Sylwester P Rogula, Hubert M Mutwil, Aleksandra Gąsecka, Marcin Kurzyna, Krzysztof J Filipiak
Cardiology journal 2021Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients' needs.
Sylwester P Rogula, Hubert M Mutwil, Aleksandra Gąsecka, Marcin Kurzyna, Krzysztof J Filipiak. Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding? Cardiology journal. 2021;28(6):954-961
PMID: 33200814
View Full Text